These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 17125250)

  • 1. Fragment-based drug design: how big is too big?
    Hajduk PJ
    J Med Chem; 2006 Nov; 49(24):6972-6. PubMed ID: 17125250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.
    Rajamani R; Good AC
    Curr Opin Drug Discov Devel; 2007 May; 10(3):308-15. PubMed ID: 17554857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand specificity in fragment-based drug design.
    Barelier S; Pons J; Gehring K; Lancelin JM; Krimm I
    J Med Chem; 2010 Jul; 53(14):5256-66. PubMed ID: 20575554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling of hydration in drug design.
    Mancera RL
    Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physics-based methods for studying protein-ligand interactions.
    Huang N; Jacobson MP
    Curr Opin Drug Discov Devel; 2007 May; 10(3):325-31. PubMed ID: 17554859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand efficiency indices as guideposts for drug discovery.
    Abad-Zapatero C; Metz JT
    Drug Discov Today; 2005 Apr; 10(7):464-9. PubMed ID: 15809192
    [No Abstract]   [Full Text] [Related]  

  • 9. Fragment-based lead discovery: leads by design.
    Carr RA; Congreve M; Murray CW; Rees DC
    Drug Discov Today; 2005 Jul; 10(14):987-92. PubMed ID: 16023057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico identification of bioisosteric functional groups.
    Ertl P
    Curr Opin Drug Discov Devel; 2007 May; 10(3):281-8. PubMed ID: 17554854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.
    Fauman EB; Rai BK; Huang ES
    Curr Opin Chem Biol; 2011 Aug; 15(4):463-8. PubMed ID: 21704549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability.
    Waring MJ
    Bioorg Med Chem Lett; 2009 May; 19(10):2844-51. PubMed ID: 19361989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular optimization using computational multi-objective methods.
    Nicolaou CA; Brown N; Pattichis CS
    Curr Opin Drug Discov Devel; 2007 May; 10(3):316-24. PubMed ID: 17554858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based maximal affinity model predicts small-molecule druggability.
    Cheng AC; Coleman RG; Smyth KT; Cao Q; Soulard P; Caffrey DR; Salzberg AC; Huang ES
    Nat Biotechnol; 2007 Jan; 25(1):71-5. PubMed ID: 17211405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs in other drugs: a new look at drugs as fragments.
    Siegel MG; Vieth M
    Drug Discov Today; 2007 Jan; 12(1-2):71-9. PubMed ID: 17198975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular complexity analysis of de novo designed ligands.
    Boda K; Johnson AP
    J Med Chem; 2006 Oct; 49(20):5869-79. PubMed ID: 17004702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E-novo: an automated workflow for efficient structure-based lead optimization.
    Pearce BC; Langley DR; Kang J; Huang H; Kulkarni A
    J Chem Inf Model; 2009 Jul; 49(7):1797-809. PubMed ID: 19552372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design.
    Du QS; Huang RB; Wei YT; Pang ZW; Du LQ; Chou KC
    J Comput Chem; 2009 Jan; 30(2):295-304. PubMed ID: 18613071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo drug design.
    Hartenfeller M; Schneider G
    Methods Mol Biol; 2011; 672():299-323. PubMed ID: 20838974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.